new ORAL agent for rheumatoid arthritis, Xeljanz (ZEL-jans, tofacitinib)

January 2013

You'll hear about a new ORAL agent for rheumatoid arthritis, Xeljanz (ZEL-jans, tofacitinib).

Xeljanz is the first Janus kinase (JAK) inhibitor. Janus kinases are enzymes linked to inflammation in joints and other tissues.

It's not a first-line agent. It's for patients who have failed or can't tolerate methotrexate.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote